AbbVie: Parkinson Disease trials

The registry lists 46 Parkinson Disease studies with AbbVie as lead sponsor. 6 are open to participants now and 21 have results posted.

Phase 1 8Phase 2 1Phase 3 18Phase 4 1No phase 18(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Assess Change in Disease Symptoms in Adult Participants With Advanced Parkinson Disease Using Subcutaneous Foslevodopa/Foscarbidopa in BelgiumRecruitingNCT07382440
• Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants Earlier Within Advanced Parkinson DiseaseRecruitingNCT07227896
• Expanded Access to TavapadonAvailableNCT07158827
• Real-World Study of Foslevodopa/Foscarbidopa to Assess Quality of Life Outcomes in Adult Participants With Advanced Parkinson DiseaseRecruitingNCT06965374
• Study on Practical ExperienceS of Treatment With Foslevodopa/foScaRbidopa in Advanced Parkinson's DiseaseRecruitingNCT06937034
• Study to Assess Real Life Effectiveness of Foslevodopa/Foscarbidopa in Adult German Participants at Initial Stages of Advanced Parkinson's Disease (EARLY-FOS)RecruitingNCT06916507
• Flexible-Dose, Adjunctive Therapy Trial in Adults With Parkinson's Disease With Motor Fluctuations (TEMPO-3)CompletedNCT04542499Phase 3Results posted
• Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's DiseaseCompletedNCT04380142Phase 3Results posted
• Flexible-Dose Trial in Early Parkinson's Disease (PD)CompletedNCT04223193Phase 3Results posted
• Fixed-Dose Trial in Early Parkinson's Disease (PD)CompletedNCT04201093Phase 3Results posted
• A Study to Evaluate the Safety and Tolerability of ABBV-951 in Subjects With Parkinson's Disease (PD)CompletedNCT03781167Phase 3Results posted
• COmedication Study Assessing Mono- and cOmbination Therapy With Levodopa-carbidopa inteStinal GelCompletedNCT03362879Results posted
• A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)CompletedNCT02799381Phase 3Results posted
• A Study to Examine the Effect of Levodopa-Carbidopa Intestinal Gel (LCIG) Therapy Relative to That of Optimized Medical Treatment (OMT) on Non-motor Symptoms (NMS) Associated With Advanced Parkinson's Disease (PD)CompletedNCT02549092Phase 3Results posted
• Patient- and Caregiver-reported Symptoms and Outcomes With Levodopa/Carbidopa Intestinal Gel for the Treatment of Advanced Parkinson's DiseaseCompletedNCT02289729Results posted
• A Study to Assess the Efficacy, Safety and Tolerability of ABT-SLV187 Monotherapy in Subjects With Advanced Parkinson's Disease (PD) and Persistent Motor Complications, Despite Optimized Treatment With Available Anti-Parkinsonian MedicationsCompletedNCT01960842Phase 3Results posted
• Duodopa Home Titration Using Telemedicine: Evaluation of Use of ResourcesCompletedNCT01956032Results posted
• Global REsponsE During iNFusIon of a gEl With LevoDopa/CarbidopaCompletedNCT01754129Results posted
• A Post Marketing Observational Study of Activities of Daily Living in Advanced Parkinson's Disease Patients With Early Troublesome Motor Fluctuations and Treated With Duodopa - a Multi-country StudyCompletedNCT01747655Results posted
• A Study to Assess the Safety and Efficacy of Levodopa-carbidopa Intestinal Gel (LCIG) for the Treatment of Non-motor Symptoms in Patients With Advanced Parkinson's DiseaseCompletedNCT01736176Phase 3Results posted
• Study of Safety, Tolerability, Pharmacokinetics, and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's DiseaseCompletedNCT01479127Phase 2Results posted
• Open Label Continuation Treatment Study With Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's DiseaseCompletedNCT00660673Phase 3Results posted
• Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's SubjectsCompletedNCT00660387Phase 3Results posted
• Safety/Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Parkinson's SubjectsCompletedNCT00360568Phase 3Results posted
• Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's SubjectsCompletedNCT00357994Phase 3Results posted
• Levodopa-Carbidopa Intestinal Gel Open-Label Study in Advanced Parkinson's DiseaseCompletedNCT00335153Phase 3Results posted
• Long-term Study of Duodopa (Levodopa/Carbidopa) in Advanced Parkinson's: Health Outcomes & Net Economic ImpactCompletedNCT00141518Phase 4Results posted
• Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's DiseaseActive, not recruitingNCT06107426
• An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's DiseaseActive, not recruitingNCT05916157
• Multiple-dose Trial to Determine the Clinical Bioequivalence Between Tavapadon Tablets in Participants With Parkinson's DiseaseCompletedNCT05610189Phase 1
• Study to Evaluate the Effects of Cytochrome P450 (CYP) 3A4 Inducer Carbamazepine on Tavapadon Pharmacokinetics in Healthy Adult ParticipantsCompletedNCT05581823Phase 1
• Study to Assess How ABBV-951 is Absorbed When Administered at Different Subcutaneous Sites of Adult Participants With Parkinson's DiseaseCompletedNCT05094050Phase 1
• Open-label Trial in Parkinson's Disease (PD)CompletedNCT04760769Phase 3
• Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's DiseaseCompletedNCT04750226Phase 3
• Study to Assess Participant/Caregiver/Investigator Satisfaction of Video-Assisted Telenursing in Adult Participants With Parkinson's Disease Treated With Levodopa-Carbidopa Intestinal GelCompletedNCT04500106
• Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's DiseaseCompletedNCT04379050Phase 3
• A 2-Part Trial of CVL-751 in Subjects With Parkinson's DiseaseCompletedNCT04295642Phase 1
• A Study to Evaluate the Safety and Tolerability of ABBV-0805 in Patients With Parkinson's DiseaseWithdrawnNCT04127695Phase 1
• A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient EnvironmentCompletedNCT03374917Phase 1
• A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's DiseaseCompletedNCT03033498Phase 1
• Special Drug Use-results Survey of Duodopa Enteral Solution in Patients With Parkinson's DiseaseCompletedNCT02906488
• Observational Study Evaluating Long-Term Effectiveness of Duodopa/Duopa in Patients With Advanced Parkinson's DiseaseCompletedNCT02611713
• Observational Study Evaluating Long-term Health Outcomes of Canadian DUODOPA-treated PatientsCompletedNCT02485600
• Health Related Quality of Life in LCIG Patients and LCIG Eligible Patients Continuing Oral TherapyCompletedNCT02381444
• An Extension Study to Assess the Safety, Tolerability and Efficacy of ABT-SLV187 in Subjects With Advanced Parkinson's Disease and Persistent Motor-Complications Despite Optimized Treatment With Available Anti-Parkinsonian MedicationsCompletedNCT02082249Phase 3
• A Pharmacokinetic Study of Levodopa and Carbidopa Intestinal Gel in Subjects With Advanced Parkinson's DiseaseCompletedNCT01484990Phase 1